Calcico is a venture backed biotechnology company focused on the development of novel CRAC channel inhibitors.
The company aims to develop selective small molecules to treat atopic dermatitis where there is clear evidence linking CRAC to human disease.
Calcico was spun-out from Oxford University in April 2012 and funded by Advent Life Sciences and Imperial Innovations. The company has developed proprietary ‘know-how’ comprising novel systems for selective CRAC channel screening and molecule characterisation. This puts us in a unique position to achieve the goal of potent and selective CRAC channel inhibition, which has so far eluded pharmaceutical companies.